{
  "ticker": "JNJ",
  "target_date": "2024-12-31",
  "actual_date": "2024-12-31",
  "collected_at": "2025-12-08T11:12:57.160590",
  "price": {
    "open": 139.49,
    "high": 140.37,
    "low": 139.05,
    "close": 140.32455444335938,
    "volume": 5811400,
    "change_1d_pct": 0.89,
    "change_7d_pct": 0.72,
    "change_30d_pct": -5.34
  },
  "technicals": {
    "rsi_14": 36.9,
    "sma_20": 142.28,
    "sma_50": 147.87,
    "macd": -2.288,
    "macd_signal": -2.417,
    "macd_histogram": 0.129,
    "bb_upper": 147.26,
    "bb_lower": 137.3,
    "price_vs_sma20_pct": -1.38,
    "price_vs_sma50_pct": -5.1,
    "volume_ratio": 0.68
  },
  "fundamentals": {
    "market_cap": 488821882880,
    "pe_ratio": 19.583977,
    "forward_pe": 19.140566,
    "price_to_book": 6.1580725,
    "price_to_sales": 5.3046904,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.37,
    "pct_from_52w_low": 44.22
  },
  "macro": {
    "spy": {
      "price": 580.99,
      "change_1d_pct": -0.36,
      "change_7d_pct": -0.86
    },
    "vix": {
      "level": 17.35,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.57
    },
    "dollar_index": {
      "level": 108.49
    },
    "gold": {
      "price": 2629.2
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note",
      "source": "Yahoo",
      "datetime": 1735685119,
      "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $144.62, representing a +0.89% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=7832f82998d3a9589dce1fad1afc41ce1e35870c4dd80432f886864e96970b77"
    },
    {
      "headline": "Is Johnson & Johnson (JNJ) Among the Best Low Volatility Stocks to Buy Right Now?",
      "source": "Yahoo",
      "datetime": 1735671479,
      "summary": "We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best low volatility stocks to buy right now. The market has shown strong performance overall, with the S&P 500 up nea",
      "url": "https://finnhub.io/api/news?id=4701cbef955c2893ca9936797fa0ac1d710f7f9d22e20c9ad3e8fcd5e0645058"
    },
    {
      "headline": "Investors in Johnson & Johnson (NYSE:JNJ) have unfortunately lost 8.8% over the last three years",
      "source": "Yahoo",
      "datetime": 1735650013,
      "summary": "For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...",
      "url": "https://finnhub.io/api/news?id=08dc8a23465e19442f65b6153f91e115a3a0e33b62dbbd85235fe97f88ba217b"
    },
    {
      "headline": "Here\u2019s Why WisdomTree U.S. LargeCap Dividend Fund (DLN) Is One of the Best Performing Dividend ETFs in 2024",
      "source": "Yahoo",
      "datetime": 1735637439,
      "summary": "We recently compiled a list of the 10 Best Performing Dividend ETFs In 2024. In this article, we are going to take a look at where WisdomTree U.S. LargeCap Dividend Fund (NYSE:DLN) stands against the other dividend ETFs. By the end of 2023, the global ETF market had reached $11.1 trillion in assets ",
      "url": "https://finnhub.io/api/news?id=e8c64d503b3d2a9869c224ffd6e8eef0fe4405f674b43240bf083e5fd241420d"
    },
    {
      "headline": "Johnson & Johnson - European Commission approves RYBREVANT in combination with LAZCLUZE for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer",
      "source": "Finnhub",
      "datetime": 1735627152,
      "summary": "BEERSE, BELGIUM - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission has approved a Type II variation extension of indication for RYBREVANT , in...",
      "url": "https://finnhub.io/api/news?id=390b8034457c7b48ce3cbbe72b765621fc925c8a2c08c3f2c07cf4a1507bf9e7"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734042449.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000106/xslF345X05/wk-form4_1734042449.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041779.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000104/xslF345X05/wk-form4_1734041779.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041373.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000102/xslF345X05/wk-form4_1734041373.xml"
    },
    {
      "form": "13F-HR",
      "date": "2024-11-13",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445424000604/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "10-Q",
      "date": "2024-10-23",
      "description": "jnj-20240929.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000096/jnj-20240929.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}